ALK to start phase I trial of peanut allergy tablet vaccine

In 2021, ALK announced that it was preparing for clinical trials of a peanut allergy treatment, and it has now relayed that the firm will soon start recruitment for an upcoming study.

Photo: Claus Bonnerup

ALK is starting its clinical trial of a tablet vaccine against peanut allergies, it reveals in a press release.

The company’s new tablet vaccine will be tested in a clinical phase I study. The trial will be called Alliance and take place in North America.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs